ENDPOINTS NEWS1h
No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra
Novo Nordisk and Viking Therapeutics took to the annual Liver Meeting to make the case for their experimental MASH drugs as ...
ENDPOINTS NEWS5h
Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor
Chris Boshoff will become Pfizer's chief scientific officer and R&D president on January 1, replacing Mikael Dolsten. Roger ...
ENDPOINTS NEWS5h
Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship
Former Pfizer exec Angela Hwang is joining Flagship Pioneering as a CEO-partner and chief executive of its startup Metaphore ...
ENDPOINTS NEWS6h
Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer
Pfizer is enlisting another Flagship startup to help it create new obesity medicines. After June's ProFound tie-up, Pfizer ...
ENDPOINTS NEWS20h
GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out
GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...
ENDPOINTS NEWS21h
NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend
The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...
ENDPOINTS NEWS22h
FDA re­jects Astel­las’ ef­fort to sup­port longer use of eye drug Iz­er­vay
The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data ...
ENDPOINTS NEWS22h
Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion
Tianjin Darentang Jingwanhong Pharmaceutical received an FDA warning letter for concealing manufacturing information, ...
ENDPOINTS NEWS22h
BeiGene set­tles fi­nal suit over fu­ture Brukin­sa gener­ics
BeiGene has settled a lawsuit with generics manufacturer MSN Pharmaceuticals, resolving all cases associated with the entry ...
ENDPOINTS NEWS1d
Lil­ly’s oral car­dio drug that blocks lipids pass­es mid-stage test
Eli Lilly's oral drug muvalaplin showed significant reductions in lipoprotein(a) levels in a Phase 2 trial of 233 high-risk ...
ENDPOINTS NEWS1d
J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster
Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the ...
ENDPOINTS NEWS1d
Bris­tol My­ers takes on au­toim­mune dis­eases with cell ther­a­py, plus new da­ta from Ca­balet­ta and Kyver­na
T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...